No Data
No Data
Nanmo Biotech (688265.SH): Shareholders intend to inquire about the transfer of 1.15% of the shares.
Gelonghui, September 9th, Nanmo Biotechnology (688265.SH) announced that the shareholders participating in the pre-IPO shareholder inquiry transfer of Nanmo Biotechnology are Shenzhen Qianhai Rongfeng Investment Partnership Enterprise (Limited Partnership); the total number of shares to be transferred by the transferor is 896,581 shares, accounting for 1.15% of the total share capital of Nanmo Biotechnology; this inquiry transfer is a non-public transfer, and will not be conducted through centralized bidding or block trading, and does not constitute a secondary market share sale. The transferee shall not transfer the shares acquired through the inquiry transfer within 6 months after the transfer.
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Nanmo Bio (688265.SH) released its performance for the first half of the year, with a net loss of 9.1436 million yuan.
Nanmo Biotechnology (688265.SH) released its 2024 interim report, and during the reporting period, the company achieved revenue of 1...
Southern Mo Biotechnology (688265.SH): The net loss in the first half of the year was 9.1436 million yuan.
On August 28, Ge Long Hui announced its 2024 interim report, reporting a revenue of 0.177 billion yuan, a year-on-year decrease of 2.17%; net income attributable to shareholders of the listed company was -9.1436 million yuan.
Gelonghui Fund Daily Report | Public fund baijiu holdings have dropped to as low as 10%! Wan Minyuan increased holdings.
Focus on the latest news in the fund.
No Data
No Data